Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Versican accumulation drives Nos2 induction and aortic disease in Marfan syndrome via Akt activation

  • Ruiz-Rodríguez, María Jesús
  • Oller, Jorge
  • Martínez-Martínez, Sara
  • Alarcón-Ruiz, Iván
  • Toral, Marta
  • Sun, Yilin
  • Colmenar, Ángel
  • Méndez-Olivares, María José
  • López-Maderuelo, Dolores
  • Kern, Christine B.
  • Nistal Herrera, Juan Francisco
  • Evangelista, Arturo
  • Teixido-Tura, Gisela
  • Campanero, Miguel R.
  • Redondo, Juan Miguel
The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation), the CBMSO is supported by Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid. CBMSO and CNIC are Severo Ochoa Centers of Excellence (grants CEX2021-001154-S and CEX2020-001041-S, respectively) funded by MICIN/AEI/10.13039/501100011033. The project leading to these results has received funding from “La Caixa” Banking Foundation under project codes HR18-00068 (to MRC and JMR); Spanish Ministerio de Ciencia e Innovación grant RTI2018-099246-BI00 (MICIU/AEI/FEDER, UE) to JMR, and grants PID2020-115217RB-100 and PID2021-122388OB-100 to MRC and JMR, respectively, funded by MCIN/AEI/10.13039/501100011033; Instituto de Salud Carlos III (CIBER-CV CB16/11/00264 and CB16/11/00479; and grants PI17/00381 to GT-T and PI21/00084 (co-funded by Fondo Europeo de Desarrollo Regional (FEDER)) to JFN); Fundacio La Marato TV3 (20151330 to JMR); Instituto de Investigación Sanitaria Marqués de Valdecilla (IDIVAL) (INNVAL 21/24) to JFN; The Marfan Foundation USA Faculty grant 2017 MRF/1701 (to JMR); Fundación MERCK; Fundación Española de Enfermedades Raras 2022 and V-Ayudas “Muevete por los que no pueden 2021” (to JO); and Spanish Ministerio de Ciencia e Innovación contracts FPI (BES-2016-077649) to MJR-R; Sara Borrell (CD18/00028) and Juan de la Cierva (IJC2020-044581-I) to MT; Ramón y Cajal (RYC2021-033343-I) to JO; and FPU (20/04814) to IA-R.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GADD45A suppression contributes to cardiac remodeling by promoting inflammation, fibrosis and hypertrophy

  • Rostami, Adel
  • Palomer, Xavier
  • Pizarro-Delgado, Javier
  • Peña, Lucía
  • Zamora, Mònica
  • Montori-Grau, Marta
  • Barroso, Emma
  • Valenzuela-Alcaraz, Brenda
  • Crispi, Fàtima
  • Salvador Sánchez, Jesús María
  • García, Raquel
  • Hurlé, María A
  • Nistal, Francisco
  • Vázquez-Carrera, Manuel
Supplementary Information The online version containssupplementary material available at https://doi.org/10.1007/s00018-025-05704-x, The growth arrest and DNA damage inducible 45A (GADD45A) is a multifaceted protein associated with stress signaling and cellular injury. Aside its well-established tumor suppressor activity, recent studies point to additional roles for GADD45A, including the regulation of catabolic and anabolic pathways, or the prevention of inflammation, fibrosis, and oxidative stress in some tissues and organs. However, little is known about its function in cardiac disease. In this study, we aimed to evaluate the role of GADD45A in the heart by using mice with constitutive and systemic deletion of Gadd45a, and cardiac cells of human origin. Gadd45a suppression in knockout mice triggered cardiac fibrosis, inflammation, and apoptosis, and these changes correlated with an hyperactivation of the pro-inflammatory and pro-fibrotic transcription factors activator protein-1 (AP-1), nuclear factor-κB (NF-κB), and signal transducer and activator of transcription 3 (STAT3). Deletion of Gadd45a also resulted in substantial cardiac hypertrophy, which negatively impacted cardiac morphology and function in knockout mice. Consistent with this, GADD45A overexpression in human AC16 cardiomyocytes partially prevented the inflammatory and fibrotic responses induced by tumor necrosis factor-α (TNF-α). Overall, data presented in this study highlight an important role for GADD45A in the heart, since it may prevent inflammation, fibrosis, and apoptosis, and, by this means, preserve cardiac function and performance. Since fibrosis and inflammation are crucial in the progression of cardiac hypertrophy and subsequent heart failure, these results suggest that promoting the activity of this protein might be a promising therapeutic strategy to slow down the progression of these deleterious diseases., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was partly supported by the grants PID2021-122116OB-I00 (M.V.-C. and X.P.), funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and “ERDF, A Way of Making Europe”, and the “Fundació La Marató de TV3” to M.V-C. CIBER in Diabetes and Associated Metabolic Diseases (CIBERDEM), CIBER of Rare Diseases (CIBERER), and CIBER in Cardiovascular Diseases (CIBERCV) are Carlos III Health Institute projects. Support was also received from the CERCA Programme/Generalitat, and from grants PI21/00084 (Carlos III Health Institute) and INNVAL21/24 (IDIVAL) to F.N., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interferon stimulated gene 15 (ISG15) modulates phenotype of vascular smooth muscle cells and pathological vascular remodeling El gen estimulado por interferón 15 (ISG15) modula el fenotipo de células musculares lisas vasculares y el remodelado vascular patológico

  • Soudant, Julius
  • González-Blázquez, Raquel
  • Merino, Abraham
  • Ballesteros-Martínez, Constanza
  • Rodrigues-Diez, Raquel
  • Moreno-Carriles, Rosa
  • Nistal, J. Francisco
  • Guerra, Susana
  • Redondo, Juan Miguel
  • Salaices, Mercedes
  • Briones, Ana M
  • García-Redondo, Ana B
Introduction: Inflammation is a major determinant of abdominal aortic aneurysms (AAA). Interferon stimulated gene 15 (ISG15) has a role in vascular remodelling in AAA. This study investigates the mechanisms whereby ISG15 might affect vascular remodeling and function. Methods: We used vascular smooth muscle cells (VSMC) from wild type (ISG15) o ISG15 knockout (ISG15) mice, aorta from ISG15 and ISG15 mice infused with angiotensin II (1.44 mg/kg/day, sc, 14 days), and human AAA. We also performed a model of recombinant ISG15 infusion (rISG15, sc, 100 and 500 ng/day, 14 days) in mice. Results: In VSMC, ISG15 deficiency increased the expression of contractile (Acta2, Tagln) and synthetic (Fn1, Col1a2, Col3, Col4) markers and decreased the expression of the calcification marker Spp1. Ang II infusion changed the expression of phenotype markers differently in aorta from ISG15 or ISG15 mice. ISG15 expression showed a negative correlation with expression of contractile markers (ACTA2, CNN1), and with COL3a1, in human samples from patients with AAA or with stenotic aorto-iliac pathology. rISG15 infusion induced hypotrophic vascular remodelling in mesenteric arteries without affecting vascular mechanics. Aorta of ISG15 mice contracted more to thromboxane A analogue U46619, compared to ISG15mice. Both aorta and mesenteric arteries from rISG15-treated mice showed less contractility than control mice. Conclusions: ISG15 participates in pathological vascular remodeling probably by modulating VSMC phenotype. These changes could also impact in the vascular function., This work was undertaken thanks to funding from the Spanish Arteriosclerosis Foundation (FEA Grant 2021- Basic Research). In addition, the study received funding from MCIN/AEI/10.13039/501100011033 and from ’’ERDF A way of making Europe’’, PID2020-116498RB-I00, through the RED2022-134541-T research networks funded by MICIU/AEI/10. 13039/501100011033 and PI21/00084, from the Social Security Health Research Fund